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Objective: Our goal was to evaluate the association of APOE with amyloid deposition,
cerebrospinal ﬂuid levels (CSF) of Aβ, tau, and p-tau, brain atrophy, cognition and cognitive
complaints in E-MCI patients and cognitively healthy older adults (HC) in the ADNI-2
cohort.
Methods: Two-hundred and nine E-MCI and 123 HC participants from the ADNI-2 cohort
were included. We evaluated the impact of diagnostic status (E-MCI vs. HC) and APOE
ε4s t a t u s( ε4 positive vs. ε4 negative) on cortical amyloid deposition (AV-45/Florbetapir
SUVR PET scans), brain atrophy (structural MRI scans processed using voxel-based
morphometry and Freesurfer version 5.1), CSF levels of Aβ, tau, and p-tau, and cognitive
performance and complaints.
Results: E-MCI participants showed signiﬁcantly impaired cognition, higher levels of
cognitive complaints, greater levels of tau and p-tau, and subcortical and cortical atrophy
relative to HC participants (p < 0.05). Cortical amyloid deposition and CSF levels of Aβ
were signiﬁcantly associated with APOE ε4 status but not E-MCI diagnosis, with ε4
positive participants showing more amyloid deposition and lower levels of CSF Aβ than
ε4 negative participants. Other effects of APOE ε4 status on cognition and CSF tau levels
were also observed.
Conclusions: APOE ε4 status is associated with amyloid accumulation and lower CSF
Aβ, as well as increased CSF tau levels in early prodromal stages of AD (E-MCI) and
HC. Alternatively, neurodegeneration, cognitive impairment, and increased complaints are
primarily associated with a diagnosis of E-MCI. These ﬁndings underscore the importance
of considering APOE genotype when evaluating biomarkers in early stages of disease.
Keywords: apolipoprotein E (APOE), early mild cognitive impairment (E-MCI), Florbetapir/AV-45/Amyvid, positron
emission tomography (PET), magnetic resonance imaging (MRI), cerebrospinal ﬂuid (CSF), Alzheimer’s disease
neuroimaging initiative (ADNI)
INTRODUCTION
Alzheimer’s disease (AD) is the most common age-related neu-
rodegenerative disease, featuring cognitive decline, accumulation
ofamyloidplaquesandneuroﬁbrillarytangles, andextensive neu-
rodegeneration (Alzheimer’s Association, 2011; McKhann et al.,
2011). The most commonly accepted prodromal AD stage is
mild cognitive impairment (MCI), which is characterized by
clinically-relevant cognitive dysfunction in the absence of signif-
icant interference with daily functioning (Petersen et al., 1999;
Albert et al., 2011). Amnestic MCI features marked memory
impairments which are predictive of progression to clinical AD.
Recently, MCI patients have been classiﬁed into two forms based
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on severity: early MCI (E-MCI) and late MCI (L-MCI). Relative
to an age-appropriate normative level, E-MCI patients show an
approximately 1–1.5 standard deviation (SD) decline in memory,
while L-MCI patients show a 1.5 SD or greater decline. These
designated cut-offs for E-MCI and L-MCI have not been fully
explored to date. However, the identiﬁcation of participants with
a 1–1.5 SD deﬁcit in memory as E-MCI may be more sensitive for
identifying participants in the earliest stages of cognitive decline.
However, the speciﬁcity of these diagnostic criteria has yet to be
determined and may be lower than the L-MCI cut-offs, allowing
participants with more diverse causal factors of cognitive decline
(other than prodromal AD) to be included in this diagnostic cat-
egory. Future studies examining these clinical criteria and clinical
and pathological outcomes of identiﬁed E-MCI patients relative
to L-MCIpatients will be important for understanding the cogni-
tive changes observed in these patients. Importantly, these new
guidelines provide an opportunity to evaluate the role of AD
biomarkers and other potential disease-causing factors in a very
early clinical stage. In fact, a recent study demonstrated increased
amyloid binding measured using [18F]Florbetapir positron emis-
sion tomography (PET) in patients with E-MCI relative to HC,
butno alterations in metabolism as assessed using [18F]FDGPET
(Wu et al., 2012).
The most common genetic variant associated with late-onset
AD is the apolipoprotein E (APOE) ε4 allele (Corder et al., 1993;
Bertram et al., 2010) .T h ep r e s e n c eo fa nε4 allele confers a
signiﬁcantly higher likelihood of developing AD. APOE genotype
is also associated with AD biomarkers, with the presence of
an APOE ε4 allele associated with greater amyloid deposition
(Drzezga et al., 2009; Morris et al., 2010; Fleisher et al., 2011), a
higher degree and faster rate of neurodegeneration (M o f f a te ta l . ,
2000; Caroli and Frisoni, 2010), alterations in brain function
and glucose metabolism (Bookheimer et al., 2000; Bondi et al.,
2005; Langbaum et al., 2009), changes in cerebrospinal ﬂuid
(CSF) measures of amyloid and tau (Vemuri et al., 2010; Tosun
et al., 2011), as well as more impaired cognition (Mayeux et al.,
2001; Farlow et al., 2004; Caselli et al., 2011)i np a t i e n t sw i t h
L-MCI and AD and cognitively healthy older adults (HC).
H o w e v e r ,t h er o l eo fAPOE genotype in E-MCI has not been
assessed. Therefore, the goal of this study is to evaluate the effect
of APOE ε4 status on amyloid deposition, neurodegeneration,
and cognition in patients diagnosed with E-MCI, the earliest
clinically-deﬁned prodromal stage of AD.
MATERIALS AND METHODS
ALZHEIMER’S DISEASE NEUROIMAGING INITIATIVE (ADNI)
ADNI was launched in 2004 by the National Institute on
Aging (NIA), the National Institute of Biomedical Imaging and
Bioengineering (NIBIB), the Food and Drug Administration
(FDA), pharmaceutical companies, and non-proﬁt organiza-
tions, as a multi-year public-private partnership. The Principal
Investigator is Michael W. Weiner, MD, VA Medical Center and
UCSF. ADNI is a longitudinal study, ultimately including more
than 1200 participants (aged 55–90) recruited from over 50 sites
across the United States and Canada. Further information can be
found at http://www.adni-info.org/ and in previous reports (Jack
et al., 2010; Jagust et al., 2010; Petersen et al., 2010; Saykin et al.,
2010; Trojanowski et al., 2010; Weiner et al., 2010). Appropriate
Institutional Review Boards approval occurred at each ADNI site
and informed consent was obtained from each participant or
authorized representative.
PARTICIPANTS
Participants wereselected iftheyweredesignatedasE-MCIorHC
(continuing participants or newly enrolled) at the initial visit of
the ADNI-GO or ADNI-2 phases and had APOE genotype data.
The sample included 209 E-MCI patients and 123 HC. Patients
were diagnosed with E-MCI using criteria described in the
ADNI-2 procedures manual (http://www.adni-info.org/). Brieﬂy,
patients were diagnosed with E-MCI using the following criteria:
1. Subjectmusthaveasubjective memoryconcernasreported by
subject, study partner, or clinician.
2. Abnormal memory function documented by scoring within
the education adjusted ranges on the Logical Memory II sub-
scale (Delayed Paragraph Recall, Paragraph A only) from the
Wechsler Memory Scale—Revised (the maximum score is 25):
a. 9–11 for 16 or more years of education.
b. 5–9 for 8–15 years of education.
c. 3–6 for 0–7 years of education.
3. Mini-Mental State Exam score between 24 and 30 (inclusive)
( E x c e p t i o n sm a yb em a d ef o rs u b j e c t sw i t hl e s st h a n8y e a r so f
education at the discretion of the project director).
4. Clinical Dementia Rating = 0.5; Memory Box score must be at
least 0.5.
5. General cognition and functional performance sufﬁciently
preserved such that a diagnosis of Alzheimer’s disease cannot
b em a d eb yt h es i t ep h y s i c i a na tt h et i m eo ft h es c r e e n i n gv i s i t .
In addition, all participants met ADNI inclusion and exclu-
sion criteria which have been described previously (Weiner et al.,
2010) and can be found at http://www.adni-info.org/.
APOE genotyping for all participants was performed as
previously described (Saykin et al., 2010). In the present study,
we sought to evaluate the impact of the presence or absence of
an APOE ε4 allele on imaging and non-imaging phenotypes.
Therefore, all participants were divided into two groups based on
APOE ε4 status, including participants with one or more ε4 allele
(APOE ε4p o s i t i v e( ε4+); 85 E-MCI, 30 HC) and participants
without an ε4 allele (APOE ε4n e g a t i v e( ε4−); 124 E-MCI, 93
HC).
CLINICAL AND NEUROPSYCHOLOGICAL ASSESSMENTS
All clinical and neuropsychological test performance data for
included participants was downloaded from the ADNI clinical
data repository on the Laboratory of Neuro Imaging (LONI) site.
Speciﬁcally, we evaluated participant performance on the Mini-
Mental State Exam (MMSE), Alzheimer’s Disease Assessment
Scale (ADAS), Montreal Cognitive Assessment (MoCA; Total and
all sub-scores), Rey Auditory Verbal Learning Test (RAVLT; Total
score, delayed recall score, delayed recognition score), Weschler’s
Logical Memory Scale—Revised (LM; Immediate and Delayed),
Clock Drawing Test (CDT), Trailmaking Test A and B (TMT-A,
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TMT-B), Boston Naming Test (BNT), Animal Fluency, and the
American National Adult Reading Test (ANART). We also evalu-
ated clinical measures, including a measure of dementia severity
[Clinical Dementia Rating Scale (CDR), Sum of Boxes score],
general functioning [Functional Assessment Questionnaire
(FAQ)], depression [Geriatric Depression Scale (GDS)], and
stroke/vascular incident history (Modiﬁed Hachinski Scale).
Cognitive complaints were assessed using the Measure of
Everyday Cognition (E-Cog) from both the patient and an
informant. The total level of complaints on the E-Cog (overall
and within each domain) for both the participant and the
informant were assessed as percentage of items endorsed as either
“2 = questionably or occasionally worse,” “3 = consistently a
little worse,” or “4 = consistently much worse.” Items endorsed
as “9 = I don’t know” were excluded.
STRUCTURAL MRI SCANS
All available baseline 3 Tesla structural magnetic resonance imag-
i n g( M R I )s c a n sw e r ed o w n l o a d e df r o mL O N If o ri n c l u d e d
E-MCIandHCparticipants. Scanswerecorrected priorto down-
load as previously described (Jack et al., 2008, 2010). Most par-
ticipants had a minimum of two scans from the baseline visit.
All available scans were processed using voxel-based morphom-
etry (VBM) implemented in Statistical Parametric Mapping 8
(SPM8) (Ashburner and Friston, 2000) and Freesurfer version
5.1 (Dale et al., 1999; Fischl et al., 1999), as described in pre-
vious reports (Dale et al., 1999; Fischl et al., 1999; Ashburner
and Friston, 2000; Risacher et al., 2009, 2010)a n db r i e ﬂ y
below:
VBM
Scans were co-registered to a T1-weighted template, segmented
into grey matter (GM), white matter (WM), and CSF compart-
mentswithbiascorrection, unmodulatednormalizedtoMontreal
Neurologic Institute (MNI) space as 1 × 1 × 1mmvoxels,and
smoothed with an 8mm Gaussian kernel. All scans underwent
extensive quality control. Mean GM density was extracted from
all available baseline scans for target regions of interest (ROIs)
using MarsBaR (Brett et al., 2002). Since most participants had
two or more baseline MRI scans, an average GM density measure
was calculated for each ROI using the mean GM density values
extracted from each of the available baseline scans. Eighteen par-
ticipants (5 HC ε4−,2H Cε4+,5E - M C Iε4−,6E - M C Iε4+)
were excluded from the GM density analyses for missing data or
failed processing.
Automated parcellation
Freesurfer version 5.1 was used to extract volumetric and cortical
thickness measures. Similar to the VBM ROI data, values from all
availablebaselinescanswereaveragedtocreateameanvolumetric
orcortical thickness valueforeach ROI.Sevenparticipants (2 HC
ε4−,1HCε4+,2E-MCIε4−,2E - MC Iε4+)w e r ee x clude df r om
the corticalthickness andvolumetric analysesforincomplete data
or failed processing.
AMYLOID PET SCANS ([11C]FLORBETAPIR)
Pre-processed [11C]Florbetapir PET scans (Coregistered,
Averaged, Standardized Image and Voxel Size, Uniform
Resolution) were downloaded from LONI (http://adni.loni.ucla.
edu/). Before download, images were averaged, aligned to a
standard space, re-sampled to a standard image and voxel size,
smoothed to a uniform resolution and normalized to a cerebellar
GM reference region resulting in standardized uptake value ratio
(SUVR) images as previously described (Jagust et al., 2010). After
downloading, the images were aligned to each participant’s same
visit MRI scan and normalized to MNI space as 2 × 2 × 2mm
voxels using parameters from the MRI segmentation. The
normalized scans were evaluated for the effect of APOE ε4 status
on a voxel-wise basis using a two-sample t-test, masked using a
whole-brain mask, and covaried for age, gender, education, and
handedness. Signiﬁcant results were displayed at a voxel-wise
threshold of p < 0.01 [family-wise error (FWE) correction for
multiple comparisons] with a minimum cluster size (k) of 50
voxels. SPM8 was used for all processing and voxel-wise analysis.
Mean regional SUVR values were also extracted for target ROIs
using MarsBaR. Fourteen participants (6 HC ε4−,5H Cε4+,3
E-MCI ε4−)w e r ee x c l u d e df r o m[ 11C]Florbetapir analyses for
missing scan data or failed processing.
CSF BIOMARKERS
Levels of amyloid-beta 1-42 (Aβ), total tau, and phosphory-
lated tau (p-tau) were measured from all available CSF samples
as previously described (Shaw et al., 2009, 2011; Trojanowski
et al., 2010). CSF data was downloaded from the LONI site and
extracted for all included participants. Of the 332 included par-
ticipants, 44 participants (25 E-MCI and 19 HC) were missing all
CSFdata.4additionalparticipants(2E-MCI,3HC)weremissing
CSF tau data and 2 additional HC participants were missing CSF
p-tau data. Furthermore, participants with CSF levels outside 3
SDs above or below the mean were excluded, including 6 E-MCI
participants with tau levels more than 3 SDs above the mean and
2 E-MCIparticipants with p-taulevels more than 3 SDs abovethe
mean. Thus, the ﬁnal samples for CSF analyses included 288 par-
ticipants in the CSF Aβ analysis, 278 participants in the CSF tau
analysis, and 284 participants in the CSF p-tau analysis.
STATISTICAL ANALYSES
We evaluated the effect of diagnosis and APOE ε4 status on
demographics, cognition, cognitive complaints, amyloid depo-
sition, atrophy, and CSF biomarkers using two-way analysis
of covariance (ANCOVA) for continuous variables and a chi-
square test for categorical variables implemented in SPSS 19.0
(SPSS, Inc., Chicago, IL). Speciﬁcally, the effect of diagnosis
(HC vs. E-MCI), APOE ε4 status (ε4+ vs. ε4−), and the inter-
action of diagnosis and ε4 status on performance on clinical
and psychometric tests, cognitive complaints, amyloid deposi-
tion (mean SUVR from target ROIs), CSF levels of Aβ,t a u ,
and p-tau, and brain atrophy (volume, cortical thickness, and
GM density from target ROIs) were assessed. All ANCOVA
analyses were covaried for age, gender, education, and hand-
edness. The analysis of neurodegenerative measures was also
covaried for total intracranial volume (ICV). The frequency
of having one or more APOE ε4 alleles was also compared
between diagnostic groups (HC vs. E-MCI) using a chi-square
test.
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RESULTS
DEMOGRAPHICS, PSYCHOMETRIC PERFORMANCE, AND COGNITIVE
COMPLAINTS
Signiﬁcantly more E-MCI were APOE ε4+ than HC (p = 0.003),
with 85 of 209 E-MCI participants (40.7%) showing one or
more ε4 alleles relative to only 30 of 123 HC participants
(24.4%). Demographicsand psychometric performance variables
for E-MCI and HC participants stratiﬁed by APOE ε4 status are
shown in Table 1. The effect of diagnosis, ε4 status, and the inter-
action between diagnosis and ε4 status are displayed. Age was
signiﬁcantly different between diagnostic groups (p < 0.05) but
not APOE ε4 groups. A signiﬁcant interaction between diagno-
sis and ε4 status on LM Immediate and Delayed performance
was observed, with ε4+ HC showing worse performance on both
measures than ε4− HC participants but no difference by ε4s t a -
tus in E-MCI participants. A trend for a signiﬁcant interaction on
the MoCA delayed recall sub-score (p = 0.05) was also observed,
again with a signiﬁcant effect of ε4 status in HC but not E-MCI
participants. Finally, a marginally signiﬁcant interaction of diag-
nosis and ε4 status for informant complaints in the visuospatial
domain (p = 0.05) was also seen, with ε4 status having an effect
only in E-MCI participants.
Signiﬁcant effects of diagnosis on the CDR-SB, FAQ, Modiﬁed
Hachinski Total, and GDS were observed (p < 0.05), with
E-MCI participants showing a greater CDR-SB, as well as higher
scores on the FAQ, Modiﬁed Hachinski, and GDS. Differences
in psychometric performance by diagnosis were observed for
nearly every test (p < 0.05), except for the RAVLT Delayed
Recognition, CDT (Total and Copy Scores), and the MoCA
language, executive-visuospatial function, and attention sub-
scores. Signiﬁcant differences in cognitive complaints from
both the participant and the informant by diagnosis were also
observed in all domains (p < 0.001). In all cases, E-MCI partic-
ipants had worse cognition and more cognitive complaints than
HC participants.
Vascular risk factors and/or stroke history was signiﬁcantly
different by APOE ε4 status (p < 0.05), with ε4+ participants
showing lower Modiﬁed Hachinski Total scores. In addition,
ε4 status was signiﬁcantly associated with performance on a
number of psychometric tests, including the ADAS Total score,
MoCA Total score, RAVLT Total score, and the MoCA nam-
ing and attention sub-scores (p < 0.05). The effect of ε4 status
w a sa l s os i g n i ﬁ c a n ta tat r e n dl e v e lf o rT M T - A( p = 0.05). For
these comparisons, ε4+ participants demonstrated worse perfor-
mance than ε4−.
VOXEL-BASED COMPARISONS OF AMYLOID DEPOSITION
ε4+ E-MCI showed signiﬁcantly greater amyloid deposition
upon voxel-wise analysis than ε4− (Figure1; voxel-wise thresh-
old: p < 0.01 (FWE), k = 50 voxels). The most signiﬁcant clus-
ter was observed in the left orbitofrontal cortex (Figure1A).
Additional signiﬁcant clusterswere observedin the medialfrontal
FIGURE 1 | Voxel-wise association of APOE ε4 status and amyloid
deposition in E-MCI participants. Greater cortical amyloid deposition was
observed in APOE ε4+ (n = 85) relative to APOE ε4− (n = 121) E-MCI
participants. Signiﬁcant clusters were observed in the medial and lateral
frontal lobes (A), anterior and posterior cingulate (B), and lateral temporal
lobes. Surface renderings show the diffuse pattern of signiﬁcant clusters
(C). All analyses were covaried for age, gender, education, and handedness
and a voxel-wise threshold of p < 0.01 (FWE correction for multiple
comparisons) and minimum cluster size (k) of 50 voxels was considered
signiﬁcant.
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lobe/anterior cingulate cortex, the right orbitofrontal cortex,
and the posterior cingulate/precuneus (Figure1B). The surface
rendering also reﬂects the widespread pattern of signiﬁcant dif-
ferences with signiﬁcant clusters throughout the frontal, pari-
etal, and temporal lobes (Figure1C). No signiﬁcant clusters
were observed in the reverse comparison (ε4− > ε4+; data not
shown).
ROI COMPARISONS OF AMYLOID DEPOSITION
ROI results were consistent with voxel-wise ﬁndings demonstrat-
ing signiﬁcantly greater global and regional amyloid deposition
in ε4+ relative to ε4− E-MCI participants in the global cortex,
mean frontal lobe, anterior cingulate, and precuneus (Figure2).
A signiﬁcant effect of ε4 status (p < 0.001) but not diagno-
sis was observed in all ROI measures, with ε4+ participants
showinggreateramyloidthanε4−participants regardless ofdiag-
nosis (HC or E-MCI). Overall, amyloid PET results indicate
that ε4+ individuals showed greater amyloid deposition than
ε4− regardless of cognitive impairment in the earliest stages of
decline.
ROI COMPARISONS OF NEURODEGENERATION
Hippocampal neurodegeneration (volume and GM density) was
associated with diagnosis (p < 0.001; Figures3A,B)b u tn o t
APOE ε4 status. E-MCI participants showed more hippocam-
pal atrophy than HC. However, a signiﬁcant interaction effect of
diagnosis and ε4 status on mean temporal lobe cortical thickness
was observed (p = 0.008; Figure3C), with ε4+ HC participants
showingthickermean temporallobesthanallother groups.Mean
temporal lobe GM density was also signiﬁcantly associated with
diagnosis (p = 0.005) and ε4 status (p = 0.047; Figure3D), as
E-MCI patients showed smaller mean temporal lobe GM den-
sitythanHCandε4−participantsshowedsmallermeantemporal
lobe GM density than ε4+ participants.
CSF LEVELS OF Aβ, TAU, AND p-tau
CSF levels of Aβ, tau, and p-tau were signiﬁcantly affected by
diagnosis and APOE ε4 status (Figure4). Levels of CSF Aβ
were signiﬁcantly associated with ε4 status (p < 0.001), with
ε4+ participants showing lower levels of Aβ than ε4− partici-
pants (Figure4A). CSF tau levels were signiﬁcantly affected by
FIGURE 2 | Regional effects of APOE ε4 status on amyloid deposition in
E-MCI and HC participants. A signiﬁcant effect of APOE ε4s t a t u so n
regional amyloid deposition was observed (p < 0.001), including in the global
cortical mean amyloid (A), mean bilateral frontal lobes (B), anterior cingulate
(C), and precuneus (D). In all evaluated regions, APOE ε4+ E-MCI (n = 85)
and HC (n = 25) participants showed a higher mean standardized uptake
value ratio (SUVR) than APOE ε4− E-MCI (n = 121) and HC (n = 87)
participants. No signiﬁcant effect of diagnostic status was observed.
Frontiers in Aging Neuroscience www.frontiersin.org April 2013 | Volume 5 | Article 11 | 7Risacher et al. Role of APOE in E-MCI
FIGURE 3 | Temporal lobe atrophy is associated with APOE ε4s t a t u s
and diagnostic group in E-MCI and HC participants. A signiﬁcant effect of
diagnosis on neurodegeneration in the temporal lobe was observed
(p < 0.05), including in hippocampal volume (A) and grey matter (GM) density
(B), mean temporal lobe cortical thickness (C), and mean temporal lobe GM
density (D). In all evaluated regions, E-MCI participants showed more
temporal lobe atrophy than HC participants. In addition, APOE ε4s t a t u sw a s
signiﬁcantly associated with mean temporal lobe GM density, with APOE
ε4− participants showing smaller mean temporal lobe GM density than
APOE ε4+ participants. Finally, a signiﬁcant interaction effect of diagnosis
and APOE ε4 status was observed in mean temporal lobe cortical thickness,
with ε4− HC participants showing thicker mean temporal lobes than all other
groups. All analyses were covaried for age, gender, education, handedness,
and total intracranial volume (ICV). The total number of participants for each
analysis is indicated on each graph (Panels A–D). Note: Thirteen participants
were excluded from the GM density analyses, but not the cortical thickness
and volumetric analyses, for failed VBM segmentation (3 HC ε4−,2H Cε4+,
4E - M C Iε4−,4E - M C Iε4+).
both diagnosis (p = 0.041) and ε4 status (p < 0.001; Figure4B).
E-MCI patients had higher tau levels than HC participants and
ε4+ participants had higher levels than ε4− participants. Finally,
an interaction between diagnosis and ε4 status on p-tau was also
observed (p = 0.046), primarily driven by a higher level of p-tau
in ε4+ HC and E-MCI participants (Figure4C).
DISCUSSION
This study provides a comprehensive evaluation of the impact
of APOE ε4 status on cognition, cognitive complaints, amy-
loid deposition, neurodegeneration, and CSF Aβ,t a u ,a n dp - t a u
levels in E-MCI and HC. As expected, we observed a signiﬁ-
cant association of diagnosis with clinical and cognitive status.
Furthermore, diagnosis was associated with neurodegeneration
and CSF tau and p-tau levels but not with amyloid deposition.
Cognitive performance, amyloid deposition, temporal lobe atro-
phy, and CSF tau and p-tau levels were signiﬁcantly associated
with ε4 status, with ε4+ participants showing poorer cognition,
less temporal lobe atrophy, and higher CSF tau and p-tau levels.
ε4+ participants also showed greater cortical amyloid deposition
and lower CSF Aβ levels. Finally, an interaction between diagno-
sisandε4statuswasobservedformemoryperformance,temporal
lobe cortical thickness, and CSF p-tau levels. Overall, the results
suggest that APOE ε4 status impacts AD-related pathological and
clinical changes in E-MCI and HC.
The effect of APOE genotype on amyloid deposition has been
shown previously, including in middle-aged and older cognitively
healthy adults, as well as patients with L-MCI and AD (Drzezga
et al., 2009; Shaw et al., 2009; Morris et al., 2010; Fleisher et al.,
2011; Tosun et al., 2011). Biochemically, APOE genotype has
Frontiers in Aging Neuroscience www.frontiersin.org A p r i l2 0 1 3|V o l u m e5|A r t i c l e1 1| 8Risacher et al. Role of APOE in E-MCI
FIGURE 4 | Effects of APOE ε4 status and diagnosis on CSF protein
levels in E-MCI and HC participants. Diagnostic group and APOE ε4
status signiﬁcantly affected CSF levels of Aβ (A),t o t a lt a u(B), and p-tau
(C).C S FA β was signiﬁcantly associated to APOE ε4s t a t u s( p < 0.001),
with APOE ε4+ E-MCI and HC participants showing lower levels of Aβ
than APOE ε4− E-MCI and HC participants, regardless of diagnosis. Total
tau levels were signiﬁcantly affected by both diagnosis (p < 0.05) and
APOE ε4s t a t u s( p < 0.001), with E-MCI patients showing higher total tau
levels than HC participants and APOE ε4+ showing higher levels than
APOE ε4− participants. Finally, an interaction between diagnostic status
and APOE ε4 status on CSF p-tau levels was also observed (p < 0.05),
primarily driven by a higher level of p-tau in APOE ε4+ HC and E-MCI
participants relative to APOE ε4− HC and E-MCI participants. The total
number of participants in each analysis is shown for each graph (Panels
A–C). Note: See text for description of participants excluded from the
CSF analysis.
been shown to affect Aβ clearance rate, with the APOE ε4i s o -
form showing signiﬁcantly slower clearance (Deane et al., 2008;
Castellano et al., 2011; Holtzman et al., 2012). The lack of diag-
nostic effect on amyloid deposition in this study suggests that
in the earliest stages of cognitive change, APOE ε4 status has a
stronger relationship to amyloid deposition than cognitive status.
The additional ﬁndings of a diagnostic effect on cognition,
cognitive complaints, neurodegeneration, and CSF tau and p-tau
levels underscore the importance of E-MCI as a diagnostic entity.
Thus, this report has notable clinical implications, particularly
in the potential implementation and utilization of E-MCI as a
clinical diagnostic entity. Patients with E-MCI show changes in
cognition and selected biomarkers, suggesting that these individ-
uals may have a higher likelihood of clinical progression. The
association of cognition and complaints to atrophic changes,
rather than amyloid levels, supports E-MCI as an intermediate
stage with pathology beyond amyloid accumulation.
These results further support the Jack et al. model of AD
biomarkers, suggesting that changes in cognition and neurode-
generation occur after measurableamyloid accumulation(Saykin
et al., 2010; Jack et al., 2011). Additionally, APOE ε4g e n o t y p e
may alter the hypothesized sigmoidal curves, in particular amy-
loid accumulation. These results also indicate the importance
of genetic background in determining likelihood and extent of
amyloid accumulation, even in preclinical stages, which may be
particularly important in clinical trial enrollment. Further, in the
era of personalized medicine, the implications of APOE geno-
type disclosure to patients in a clinical setting must be carefully
considered, given the impact of APOE on AD risk and amyloid
deposition (Green et al., 2009; Roberts et al., 2011).
The observed greater temporal lobe cortical thickness and
GM density in ε4+ participants, particularly in HC, is some-
what unexpected and may be related to the modest sample size
of the ε4+ HC group. However, previous studies have observed
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increased cortical thickness, including in middle-aged APOE ε4
positive participants (Espeseth et al., 2008), in cognitively HC
who are transitioning to become CSF Aβ biomarker positive
(Fortea et al., 2011), and in asymptomatic patients positive for
a PSEN1 mutation more than 9 years prior to the clinical onset
(Fortea et al., 2010). Thus, future studies including longitudi-
nal follow-up with an expanded sample will be important in
determining the signiﬁcance of this ﬁnding.
The present study has a few notable limitations. First, we eval-
uated the effect of APOE ε4 status on AD biomarkers in only HC
andE-MCIratherthanacrossthediseasespectrum. Althoughour
goalwastoevaluateAPOE intheearlieststagesofAD,futurestud-
ies assessing the full clinical spectrum are warranted. In addition,
we did not evaluate all known biomarkers of AD, including FDG
PET or advanced MRI techniques (i.e., diffusion tensor imaging,
resting-state functional MRI, etc.). These measures are available
insubsetsoftheADNI-GO/2cohortandthus,futurestudieseval-
uating these measures would augment the ﬁndings of the present
report. Thirdly, genome-wide genetic data for this cohort was
recently released. Future studies assessing other variants maypro-
vide information about the role of genetics in very early stages of
AD. Finally, the present study evaluates only cross-sectional mea-
sures. Futurestudies using longitudinalandclinical outcomedata
will allow assessment of the role of APOE in progression of HC
and E-MCI.
In summary, we assessed the role of APOE ε4 status on clin-
ical and cognitive measures, cognitive complaints, and imaging
and CSF biomarkers in HC and E-MCI participants from the
ADNI-GO/2 cohort. We determined that APOE ε4 status is asso-
ciated with increased amyloid deposition in both HC and E-MCI,
while diagnostic category is associated with measures of cog-
nition and cognitive complaints, as well as neurodegeneration.
Therefore, we conclude that APOE is an important mediator of
amyloid pathology in the earliest stages of AD-associated clinical
decline.
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